Scientific Publications

2026

AACR

CAN016 – clinical study updates (CAN016, a HER2-targeted dual-payload ADC, phase 1 clinical development)
CAN017 – updates (A novel StarLinker-based, CLDN18.2/PD-L1 bispecific dual-payload ADC (CAN017) overcomes tumor heterogeneity)
CAN2109 – Phase I results (A phase 1 study of CAN2109, a novel,long-acting, tumor-retained, immunogenic cell death inducer

2025

ESMO

CAN1012 – clinical updates (Poster Title (5550): Efficacy of an IFN-α Biased TLR7 Agonist CAN1012 Alone or Combined With the Anti-PD-1 Antibody Toripalimab)

2024

SITC

CAN1012 – Phase I results disclosed at SITC (Poster 1 (No. 689) Results From A Phase I Dose Escalation Trial of CAN1012 in Patients With Solid Tumors)
CAN2109 – preclinical results disclosed (Poster 2 (No. 1345) CAN2109: Preclinical Development of A Novel Long-Acting Immunogenic Cell Death (ICD) Inducer for Cancer Therapy)

World ADC 2024

CAN016 – research updates disclosed at World ADC 2024 (Poster Title: Dual-Payload ADCs for Overcoming Drug Resistance and Tumor Heterogeneity)
StarLinker (SL) Technology: A Novel Synthetic Linker Technology Platform With Robust and High DAR and Multiple-Agent ADC Capabilities
Development of TLR-ADCs Using Novel Selective TLR7, TLR8 or TLR7/8 Dual Agonists As Payloads

2023

STING & TLR Targeting Therapies Summit

CAN1012 – research update (Poster 4380)

2022

Society for Immunotherapy of Tumors (SITC)

CAN1012 – preclinical data disclosed at the annual meeting of the Society for Immunotherapy of Tumors (SITC) (Poster title: CAN1012: A SELECTIVE AND POTENT TLR7 AGONIST WITH STRONG ANTITUMORAL PROPERTIES MEDIATED BY LOCALIZED INNATE IMMUNE ACTIVATION)